Abstract
A number of studies have compared relative survival for home hemodialysis patients (including longer hours/more frequent schedules) and other forms of renal replacement therapy. While informative, many of these studies have been limited by issues pertaining to their observational design including selection bias and residual confounding. Furthermore the few randomized controlled trials that have been conducted have been underpowered to detect a survival difference. Finally, in the face of a growing recognition of the value of patient-important outcomes beyond survival, the focus of comparisons between dialysis modalities may be changing. In this review, we will discuss the determinants of survival for patients receiving home hemodialysis and address the various studies that have compared relative survival for differing home hemodialysis schedules to each of in-center hemodialysis, peritoneal dialysis and transplantation. We will conclude this review by discussing whether there is an ongoing role for survival analyses in home hemodialysis.
Original language | English |
---|---|
Pages (from-to) | S64-S70 |
Journal | Nephrologie et Therapeutique |
Volume | 17 |
DOIs | |
Publication status | Published - Apr 2021 |
Bibliographical note
Funding Information:KT has participated in Advisory boards/consultancy work for Astra Zeneca, Otsuka, Baxter and Janssen. KT has received unrestricted grant funding from Otsuka, Canada. AV has participated in Advisory Boards/consultancy work for Paladin Labs Inc. The other author has no competing interest.
Publisher Copyright:
© 2020 Société francophone de néphrologie, dialyse et transplantation
ASJC Scopus Subject Areas
- Nephrology
PubMed: MeSH publication types
- Journal Article
- Review